Develops and manufactures animal health products. Supplies mineral nutrition products for livestock. Now — the numbers.
This is an established company with proven profits.
Average growth of 13% a year over the last 4 years. Every year shown ended in profit.
The gap is $706.8M. In times of high interest rates, a gap like that can squeeze a company.
The market pays 14.5× for every dollar of annual profit — around what a business like this usually costs.
Against companies in its own sector, it looks cheaper than 72% of them.
Analysts' average target sits 21% below today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Sales are growing strongly for its sector.
Clearly below the class average.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
The stock trades 40% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 13% a year on average.
It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.
It pays out $0.48 per share each year — regular cash for whoever holds the stock.
Over the last 12 months, executives reported 136 sells against just 14 buys. Not an alarm bell by itself, but a number worth watching.
The stock trades 21% above the average analyst price target.
On our five-subject report card, PAHC sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: PAHC is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.
Not covered, because the filings we hold do not carry it: the revenue breakdown.